On December 9, Gelonghui reported that JAK-8263 (01167.HK) announced that the company presented preliminary data from a Phase I clinical trial of the BET inhibitor JAB-8263 for the treatment of myelofibrosis (MF) at the 66th American Society of Hematology (ASH) annual meeting held in San Diego, California.

Data shows that JAB-8263 has good tolerability, with a recommended Phase II dose of 0.3 mg (administered daily). The preliminary efficacy data for JAB-8263 as a monotherapy for myelofibrosis is encouraging, with most patients experiencing a reduction in spleen volume and a decrease in the total symptom score (TSS).